

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



June 14, 2022

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SUNPHARMA

Scrip Code: 524715

Dear Sirs,

Sub: Intimation under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the disclosure of related party transactions (on consolidated basis) for the half year ended March 31, 2022 is enclosed herewith.

This is for your information and record.

Thanking you,

Yours faithfully,
For **Sun Pharmaceutical Industries Limited**

ANOOP
ANJANIKUMA
R DESHPANDE

Digitally signed by ANOOP ANJANIKUMAR DESHPANDE
DN: cn=IN, ou=Personal,
postalCode=411038, st=Maharashtra,
serialNumber=EFFDD2957A082F211A02
79A238583D8528E4413F8FAC2175693E
06E12FFD7D9, cn=ANOOP
ANJANIKUMAR DESHPANDE
Date: 2022.06.14 16:27:05 +05'30'

(Anoop Deshpande)
Company Secretary & Compliance Officer

Disclosure of Related Party Transactions for the half year ended March 31, 2022

								Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee Rs in Mn	Value of transaction during the reporting period Rs in Mn	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance Rs in Mn	Closing balance Rs in Mn	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance / inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured / unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
90	Sun Pharma (Netherlands) B.V.		Artes Biotechnology GmbH		Joint Venture	Reimbursement of expenses - Paid	Not Applicable	0.0	-	-								
91	Sun Pharma (Netherlands) B.V.		Artes Biotechnology GmbH		Joint Venture	Repayment of loan	Not Applicable	7.9	-	-								
92	Taro Pharmaceutical Industries Limited (Consolidated)		Mr. Dilip Shantilal Shanghvi		KMP	Payables (against remuneration / compensation)	Not Applicable	-	93.4	109.7								
93	Taro Pharmaceutical Industries Limited (Consolidated)		Mr. Dilip Shantilal Shanghvi		KMP	Remuneration/ compensation	Not Applicable	46.7	-	-								
94	Taro Pharmaceutical Industries Limited (Consolidated)		Mr. Sudhir Vrundavandas Valia		KMP	Payables (against remuneration / compensation)	Not Applicable	-	0.9	1.0								
95	Taro Pharmaceutical Industries Limited (Consolidated)		Mr. Sudhir Vrundavandas Valia		KMP	Remuneration/ compensation	Not Applicable	2.0	-	-								
96	Taro Pharmaceutical Industries Limited (Consolidated)		Sun Pharma Advanced Research Company Limited		Entities in which KMP and relatives of KMP have control or significant influence	Payables	Not Applicable	-	-	1.1								
97	Taro Pharmaceutical Industries Limited (Consolidated)		Sun Pharma Advanced Research Company Limited		Entities in which KMP and relatives of KMP have control or significant influence	Receiving of Service	Not Applicable	1.5	-	-								
	Total							2,029.2	3,080.6	2,921.8								

Notes:

- 1 Key Management Personnel (KMP) and Relatives of KMP who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognised as per Ind AS 19 - 'Employee Benefits'. As these employee benefits are lump sum amount provided on the basis of actuarial valuation, the same is not included above and there is no Share-based payments to KMP and relatives of KMP.
- 2 Difference in opening and closing balances are on account of transaction during the period/ exchange rate fluctuation.
- 3 Amount mentioned as "0.00" denotes value less than ₹ 50,000/-.